Biontech Se Sponsored Adr Stock News

A CDC study found that adolescents between the ages of 12 and 18 years old given the Pfizer/BioNTech COVID vaccine had a high level of protection against multisystem inflammatory syndrome.

(RTTNews) - The Centers for Disease Control and Prevention has widened the eligibility of Pfizer Inc. (PFE) and BioNTech SE''s booster doses to children aged between 12 and 15 years old. This decision follows advice from a panel which recommended that the CDC make it possible for COVID-19 booster shots be made available for children between 12

Pfizer (PFE) and BioNTech (BNTX) plan to develop an mRNA-based vaccine for shingles after witnessing success with their COVID-19 vaccine.

The Centers for Disease Control and Prevention''s independent panel of vaccine experts endorsed Pfizer and BioNTech''s Covid booster shots for children ages 12 to 15 on Wednesday, as kids return to school amid an unprecedented surge of infections across the U.S.

If successful, the vaccine could be the first mRNA shot for shingles.

Michael Yee, managing director covering healthcare equity research at Jefferies, joins CNBC's 'Squawk Box' to discuss shares of Covid-19 drugmakers Moderna and Pfizer.

Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) have announced a new research, development, and commercialization collaboration to develop a potential first mRNA-based vaccine for the preven

BioNTech: Profit Off Of Next-Gen Vaccines And Therapies

The current investor trend isn't the biotech stock's friend.

BioNTech SE - ADR (BNTX) shares closed today 10.1% lower than it did at the end of yesterday. The stock is currently down 10.1% year-to-date, up 184.4% over the past 12 months, and up 1528.2% over the past five years. Today, the Dow Jones Industrial Average rose 0.6%, and the S&P 500 rose 0.6%. Trading Activity Shares traded as high as $263.95 and as low as $231.50 this week.Shares closed 50.0% below its 52-week high and 173.1% above its 52-week low.Trading volume this week was 50.6% lower than the 10-day average and 61.4% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.6. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price lags the S&P 500 Index today, beats it on a 1-year basis, and beats it on a 5-year basis The company's share price lags the Dow Jones Industrial Average today, beats it on a 1-year basis, and beats it on a 5-year basis Per Group Comparative Performance The company's stock price performance over the past 12 months beats the peer average by -2653.2% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

FDA authorizes the booster shot of Pfizer (PFE) and BioNTech's (BNTX) COVID-19 vaccine for adolescents 12 through 15 years of age.

Investors appear to be seeing a future where COVID-19 vaccines aren't needed nearly as much.

The new approval comes as the Omicron variant surges through the US, driving up new COVID-19 cases to record highs.

Pfizer Inc. PFE, -3.95% and BioNTech SE BNTX, -4.93% announced Monday that the U.S. Food and Drug Administration has granted Emergency Use Authorization of a booster dose of the companies' COVID-19 va